Zobrazeno 1 - 10
of 244
pro vyhledávání: '"Saadettin, Kilickap"'
Autor:
Biagio Ricciuti, MD, PhD, Arielle Elkrief, MD, Jessica Lin, MD, Jianjun Zhang, MD, Joao V. Alessi, MD, Giuseppe Lamberti, MD, PhD, Malini Gandhi, MD, Alessandro Di Federico, MD, Federica Pecci, MD, Xinan Wang, PhD, Maisam Makarem, MD, PhD, Cassio Murilo Hidalgo Filho, MD, Teresa Gorria, MD, Arushi Saini, BS, Cindy Pabon, MD, James Lindsay, PhD, Kathleen L. Pfaff, PhD, Emma L. Welsh, BS, Mizuki Nishino, MD, Lynette M. Sholl, MD, Scott Rodig, MD, Saadettin Kilickap, MD, Petra Rietschel, MD, Debra AG. McIntyre, PhD, Jean-Francois Pouliot, MD, Mehmet Altan, MD, Justin F. Gainor, MD, John V. Heymach, MD, Adam J. Schoenfeld, MD, Mark M. Awad, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 9, Pp 100675- (2024)
Introduction: Responses to first-line programmed cell death protein 1 inhibition vary among patients with metastatic NSCLC and a programmed death-ligand 1 (PD-L1) tumor proportion score (TPS) greater than or equal to 50%. We previously reported impro
Externí odkaz:
https://doaj.org/article/b469726a5a6d43d08be740aa9e8f7bc9
Autor:
Seda Kahraman, Serdar Karakaya, Muhammed Ali Kaplan, Sema Sezgin Goksu, Akin Ozturk, Zehra Sucuoglu Isleyen, Jamshid Hamdard, Sedat Yildirim, Tolga Dogan, Selver Isik, Abdussamet Celebi, Burcu Belen Gulbagci, Nail Paksoy, Mutlu Dogan, Haci Mehmet Turk, Ahmet Bilici, Ali Murat Tatli, Sinem Akbas, Nedim Turan, Ilhan Hacibekiroglu, Gamze Gokoz Dogu, Adnan Aydiner, Ahmet Taner Sumbul, Serap Akyurek, Merih Yalciner, Ahmet Demirkazik, Pinar Gursoy, Musa Baris Aykan, Elif Sahin, İbrahim Karadag, Osman Kostek, Muhammed Muhiddin Er, Mehmet Artaç, Yakup Duzkopru, Dincer Aydin, Deniz Isik, Yusuf Karakas, Saadettin Kilickap, Cihan Erol, Bilgin Demir, Burak Civelek, Yakup Ergun, Muhammed Bulent Akinci, Izzet Dogan, Nuri Karadurmus, Perran Fulden Yumuk, Mehmet Ali Nahit Sendur
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-13 (2024)
Abstract Central nervous system (CNS) metastases can be seen at a rate of 30% in advanced stages for patients with non-small cell lung cancer (NSCLC). Growing evidence indicates the predictive roles of driver gene mutations in the development of brai
Externí odkaz:
https://doaj.org/article/dfd4fc84465f4b4985707fa241e217b7
Autor:
Hasan Cagri Yildirim, Fatih Kus, Deniz Can Guven, Ece Karaca, Yunus Kaygusuz, Omer Dizdar, Sercan Aksoy, Mustafa Erman, Suayib Yalcin, Saadettin Kilickap
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 6, Iss 4, Pp 170-176 (2023)
Introduction: Although immune checkpoint inhibitors (ICIs) are widely used in cancer treatment, identifying factors that predict treatment response remains a challenge in clinical practice. There is a need for biomarkers to identify patients who may
Externí odkaz:
https://doaj.org/article/67323cc7fe9e425d97196951b9a3b644
Autor:
Deniz Can Guven, Musa Baris Aykan, Harun Muglu, Ertugrul Bayram, Kaan Helvaci, Bengü Dursun, Melisa Celayir, Elvin Chelebiyev, Erdinc Nayir, Mustafa Erman, Ahmet Sezer, Yuksel Urun, Umut Demirci, Ozlem Er, Umut Disel, Ahmet Bilici, Cagatay Arslan, Nuri Karadurmus, Saadettin Kilickap
Publikováno v:
Cancer Medicine, Vol 13, Iss 1, Pp n/a-n/a (2024)
Abstract Introduction The advances in immune checkpoint inhibitors (ICIs) were relatively slow in rare tumors. Therefore, we conducted a multi‐center study evaluating the efficacy of ICI monotherapy and the combination of ICIs with chemotherapy (CT
Externí odkaz:
https://doaj.org/article/0f697c742e7245d3a185d956a2ca5f1a
Autor:
Mustafa Ozguroglu, Saadettin Kilickap, Igor Bondarenko, Ahmet Sezer, Mahmut Gümüş, Miranda Gogishvili, Xuanyao He, Giuseppe Gullo, Petra Rietschel, Ruben GW Quek
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/d567674c409344d1a377a09a1890d0a4
Publikováno v:
Dermatology Practical & Conceptual, Vol 13, Iss 3 (2023)
Introduction: We have observed that most cutaneous melanoma patients under our supervision lack characteristic phenotypical features for melanoma. In contrast; history of cancers other than melanoma and age at onset before 50 were common. This observ
Externí odkaz:
https://doaj.org/article/12e7524699834a4a9cc893f1e58acbe4
Autor:
Suayib Yalcin, Faysal Dane, Berna Oksuzoglu, Nuriye Yildirim Ozdemir, Abdurrahman Isikdogan, Metin Ozkan, Guzin Gonullu Demirag, Hasan Senol Coskun, Bulent Karabulut, Turkkan Evrensel, Mehmet Ali Ustaoglu, Feyyaz Ozdemir, Hande Turna, Tugba Yavuzsen, Faruk Aykan, Alper Sevinc, Hakan Akbulut, Deniz Yuce, Mutlu Hayran, Saadettin Kilickap
Publikováno v:
BMC Cancer, Vol 20, Iss 1, Pp 1-7 (2020)
Abstract Background Combination of gemcitabine and nab-paclitaxel has superior clinical efficacy than gemcitabine alone. Nevertheless, health-related quality of life. (QoL) associated with this combination therapy when administered at first-line in a
Externí odkaz:
https://doaj.org/article/1ae3c043ebb54a6c82250c0cb4ea7be9
Publikováno v:
Frontiers in Oncology, Vol 11 (2021)
IntroductionAfter the results of phase III vaccine studies became available, the leading oncology societies recommended two doses of COVID-19 vaccination to all patients with cancer with no specific recommendation for tumor type and active treatments
Externí odkaz:
https://doaj.org/article/f1dab24580d04d1cb62af92af96cee69
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-6 (2019)
Abstract Background The aim of this study was to evaluate the prevalence of some gynecological cancer risk factors in a population of female relatives of cancer patients in Hacettepe University Oncology Hospital. Additionally, what are the levels of
Externí odkaz:
https://doaj.org/article/66274a95db2645c796b2b47196fe758f
Autor:
Nuri Karadurmus, Mehmet Ali Nahit Sendur, Burcak Karaca, Omer Fatih Olmez, Ilhan Hacibekiroglu, Hasan Senol Coskun, Serkan Degirmencioglu, Yasemin Kemal, Saadettin Kilickap, Ahmet Taner Sumbul, Burc Aydin, Hande Turna, Muhammet Ali Kaplan, Nalan Babacan, Umut Demirci, Alper Ata, Dilek Erdem, Ahmet Ozet, Huseyin Abali
Publikováno v:
Journal of Oncological Sciences, Vol 4, Iss 3, Pp 125-129 (2018)
Objective: We aimed to evaluate the safety of nivolumab + ipilimumab (nivo + ipi) in advanced melanoma patients who had relapsed after ≥1 line of systemic treatment in a real-world setting. Methods: Adult patients with advanced melanoma who had pro
Externí odkaz:
https://doaj.org/article/b65969b72b5e41bcac86a08301fd1b4f